Skip to main content

Moleculin Biotech, Inc.

MBRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001659617

In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.

Holders of 5% or more of MBRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Moleculin Biotech, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Moleculin Biotech, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

3 Schedule 13D and 13G filings on Moleculin Biotech, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on MBRX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20259:13 PM ETArmistice Capital, LLCand 1 other13G/A4.99%1.59M shares−3.94 ppfrom 8.93%Below 5%Jun 30, 2025SEC
May 15, 20253:30 PM ETArmistice Capital, LLCand 1 other13G/A8.93%1.25M shares−1.06 ppfrom 9.99%Mar 31, 2025SEC
Feb 14, 20255:51 PM ETArmistice Capital, LLCand 1 other13G/A9.99%339.8K shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Moleculin Biotech, Inc. shares.

No Form 144 notices for Moleculin Biotech, Inc. are on file.